| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | TGF beta 1, 2 and 3 |
| Clinical data | |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6392H9926N1698O2026S44 |
| Molar mass | 144388.22 g·mol−1 |
  (what is this?) (verify) | |
Fresolimumab (GC1008) is a human monoclonal antibody[1] and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer[2][3] (kidney cancer and melanoma).
It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β).[2]
History
Fresolimumab was discovered by Cambridge Antibody Technology (CAT) scientists[4] and was one of a pair of candidate drugs that were identified for the treatment of the fatal condition scleroderma. CAT chose to co-develop the two drugs metelimumab (CAT-192) and fresolimumab with Genzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab.[5]
In February 2011 Sanofi-Aventis agreed to buy Genzyme for US$20.1 billion.[6]
As of June 2011[update] the drug was being tested in humans (clinical trials) against IPF, renal disease, and cancer.[7][8] On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis[9] comparing fresolimumab versus placebo.
As of July 2014[update], Sanofi-Aventis continue to list fresolimumab in their research and development portfolio under Phase II development.[10]
References
- ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. 23 (2). 2009.
- ^ a b "Fresolimumab". NCI Drug Dictionary. National Cancer Institute.
- ^ "Fresolimumab" (PDF). Statement on a Nonproprietary Name Adopted by the USAN Council.
- ^ Grütter C, Wilkinson T, Turner R, Podichetty S, Finch D, McCourt M, et al. (December 2008). "A cytokine-neutralizing antibody as a structural mimetic of 2 receptor interactions". Proceedings of the National Academy of Sciences of the United States of America. 105 (51): 20251–6. Bibcode:2008PNAS..10520251G. doi:10.1073/pnas.0807200106. PMC 2600578. PMID 19073914.
- ^ Foley S (10 February 2004). "CAT may abandon skin drug after trial results disappoint". The Independent. Archived from the original on 3 November 2012.
- ^ "Sanofi-Aventis to buy Genzyme in search for new sales". BBC News. 16 February 2011.
- ^ "Scientists Trigger White Fat to Become Brown Fat-Like to Treat Obesty and Type 2 Diabetes". Genetic Engineering & Biotechnology News. July 5, 2011.
- ^ "Studies found for Fresolimumab". Clinicaltrials.gov.
- ^ Clinical trial number NCT01665391 for "A Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis (FSGS)" at ClinicalTrials.gov
- ^ "R&D Portfolio". Sanofi. Archived from the original on 28 June 2014.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |
This page was last edited on 15 June 2023, at 00:03